AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04311502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine (RPT)
Description: Administered orally once daily
Study NCT05009732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Local standard of care per written policies or guidelines
Study NCT05009732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Local standard of care per written policies or guidelines
Study NCT05009732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo
Study NCT06269809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary clipping of the uterine arteries and the utero-ovarian ligmants.
Description: Temporary clipping of the uterine arteries and the utero-ovarian ligaments using laparoscopic clips/bulldog clamps, during robotically assisted myomectomy.
Study NCT06269809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No temporary clipping of the uterine arteries and the utero-ovarian ligmants.
Description: Robotically assisted myomectomy, for which no temporary clipping of the uterine arteries and the utero-ovarian ligaments
Study NCT06148545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemental iron
Description: Group A who received standard therapy (Fe preparations) 3 mg/kg BW/day
Study NCT06148545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemental iron and Vit D
Description: Group B received standard therapy (Fe preparations) 3 mg/kgBW/day combination with vitamin D, 400IU).
Study NCT04311502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Description: Administered orally once daily
Study NCT04311502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid (INH)
Description: Administered orally once daily
Study NCT04311502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (PZA)
Description: Administered based on weight orally once daily
Study NCT04311502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide (PZA)
Description: Administered based on weight orally once daily
Study NCT04311502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol (EMB)
Description: Administered based on weight orally once daily
Study NCT04311502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol (EMB)
Description: Administered based on weight orally once daily
Study NCT04979884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
Study NCT04311502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin (RIF)
Description: Administered orally once daily
Study NCT04311502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF)
Description: Administered orally once daily
Study NCT04311502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B6)
Description: All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.
Study NCT04311502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyridoxine (vitamin B6)
Description: All participants must receive pyridoxine (vitamin B6) with each dose of INH based on current local, national or international dosing guidelines. Pyridoxine is not provided by the study.
Study NCT04979884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days
Study NCT04303702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue Oxytocin
Description: The administration and titration of oxytocin for labor augmentation is per a hospital based protocol. To summarize, oxytocin is initiated intravenously at 2 milliunits/minute and increased by 2 milliunits/minute every 20 minutes until an adequate contraction pattern is attained or a maximum of 40 millunits/minute has been achieved. This protocol for titration and administration will be applied in this study to the oxytocin group. The intravenous pumps on Labor and Delivery have automated functions for intravenous administration of oxytocin that is milliunit-based and the same routine pumps will be used in this study. The study bag will be administered per current oxytocin protocol. Since patients will already be on oxytocin at time of randomization, their current bag of oxytocin will be continued by the primary provider at a rate of their discretion.
Study NCT04303702 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Discontinue Oxytocin
Description: Patients will have their oxytocin discontinued in the second stage of labor. The patient will receive routine maintenance IV fluids per the discretion of the provider.
Study NCT05666830 — intervention group
Intervention type: DEVICE
Intervention: Lando® artificial dermal regeneration matrix
Description: Participants will be treated with artificial dermis that perfomed with STSG simultaneously.
Study NCT05504499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interspinous Fusion
Description: The intended study population are adults 18 years or older with symptomatic lumbar degenerative disc disease resulting in back pain with lower extremity symptoms and neurogenic claudication that improves with spinal flexion who are candidates for use of the Zip™ MIS Interspinous Fusion device when undergoing spinal fixation procedures.
Study NCT05152602 — intervention group
Intervention type: PROCEDURE
Intervention: Bilateral Erector spinae plane block
Description: Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
Study NCT05152602 — intervention group
Intervention type: PROCEDURE
Intervention: Unilateral Erector spinae plane block
Description: Erector spinae plane (ESP) block is an interfascial plane block where a local anaesthetic is injected in a plane preferably below the erector spinae muscle. It is supposed to work at the origin of spinal nerves based on cadaveric and contrast study. It has emerged as an effective and safe analgesic regional technique. It will be done at T7-8 level
Study NCT06392711 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells (MSC) Dose Level 0
Description: 10 (8-12) x 10\^6 MSCs
Study NCT06392711 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells (MSC) Dose Level 1
Description: 20 (16-24) x 10\^6
Study NCT05394896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUMEN (Edwards Lifesciences, Irvine, USA)
Description: ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.
Study NCT05394896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Blood Pressure
Description: Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)
Study NCT06479668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Task
Description: Specify details not covered in associated Arm Description.
Study NCT05127421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream 1.5% applied twice a day (BID)
Study NCT05127421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle cream applied twice a day (BID) to affected areas
Study NCT06402812 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.
Study NCT05271396 — intervention group
Intervention type: OTHER
Intervention: Clinical Assessment
Description: The demographic information and clinical findings of the participants were recorded. Mandible movements evaluation with a digital caliper. The Visual Analogue Scale (VAS) to measure the severity of pain at rest and during activity. Cervical lordosis and shoulder posture assessment, Fonseca Anamnestic Index for TMD severity classification. Spirometric measurement to evaluate respiratory functions of all participants and intraoral pressure measurement to determine respiratory muscle strength.
Study NCT06029205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conscious Awareness-Based Educatıon
Description: The effect of Conscious Awareness-Based Education on nurses
Study NCT06029205 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stress coping training
Description: The effect of stress coping training on nurses
Study NCT05040776 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EP-7041 Injection
Description: EP-7041 infusion
Study NCT05040776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EP-7041 Injection
Description: EP-7041 infusion
Study NCT05589909 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IL27, PCT, CRP, Blood culture
Description: magnetic bead multiplex platform
Study NCT05500157 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aspiration sclerotherapy versus laparoscopic fenestration
Description: See arm description
Study NCT06380361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioSpy System
Description: One arm only - in all eligible study patients, the study device will be used. In patients with suspicion of lung cancer a bronchoscope will be inserted to navigate to the lesion where a biopsy sample will be taken for histology analysis. In the current trial, the device will be used to perform electrophysiological measurements in the lesion during bronchoscopic biopsy procedure.
Study NCT06349330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test: 3D intra-oral scanner
Description: 3D intra-oral scanner will be used to scan the subjects after plaque staining is performed. Subsequently, a 3D rendered image will be produced. Participants will be given oral hygiene education and instruction before being instructed to brush.~A cooling-off period of 30 minutes is given before participants are instructed to brush.
Study NCT06349330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Standard oral hygiene
Description: Standard oral hygiene instructions will be delivered using a hand mirror. No 3D intraoral scanner will be used.
Study NCT06556446 — intervention group
Intervention type: DRUG
Intervention: Tenecteplase and Alteplase
Description: The timepoints, dose, and type of IVT will be collected as well as any complications occuring.
Study NCT04967144 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nerve conduction study
Description: Participants with carpal tunnel syndrome will consist of individuals whose diagnosis has been confirmed by an electrophysiological study.~Participants in the control group will consist of those who have been confirmed not to have carpal tunnel syndrome by nerve conduction study.
Study NCT04967144 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment Test
Description: Montreal Cognitive Assessment Test evaluates eight separate cognitive functions. Thirty is the highest score. The scores equal to or above 26 are considered normal cognitive function.
Study NCT06350396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS treatment
Description: Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
Study NCT06350396 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS treatment
Description: The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
Study NCT06192784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Description: transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.
Study NCT06192784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pucotenlimab
Description: lenvatinib (8mg, qd) plus pucotenlimab (200mg, q3w)
Study NCT05246683 — intervention group
Intervention type: OTHER
Intervention: observational
Description: registry
Study NCT05667792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microsoft Kinect 360
Description: Balance and trunk proprioception games will be selected and played for the children to be included in the treatment. Children will play these games with their own body movements.
Study NCT05667792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pediatric Rehabilitation
Description: Bobath therapy
Study NCT05667792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Rehabilitation
Description: Bobath therapy
Study NCT04982952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management - Increasing
Description: Increasing incentive payment for abstinent participant
Study NCT05161819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses
Study NCT05161819 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: High-frequency stimulation (10Hz), 120% motor threshold, 40 trains, 1600 pulses (with sham coil)
Study NCT04982952 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fixed payments
Description: Fixed payments for attending study visits
Study NCT05334680 — intervention group
Intervention type: DEVICE
Intervention: ANNE Sensor
Description: The data collected from this sensor contains a wide range of core and novel respiratory digital biomarkers as a home-based early identification system. The core measurements include: heart rate, heart rate variability, temperature, physical activity (including sleep quality) and respiratory rate. The novel respiratory digital biomarkers include: respiratory cadence (expiration / inspiration time), coughing, swallowing, throat clearing, and talk time.
Study NCT05481203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Kaleidescope
Description: During the nasopharyngeal swab collection process, the researcher held a kaleidoscope to each child's eye, leisurely turning it and asking about the colors and shapes seen within it.
Study NCT05481203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The visual illusion cards
Description: Just before the nasopharyngeal swab participants were allowed to check the cards andwere askedwhat they saw in them.
Study NCT05726019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Oral tablet colchicine 0.5mg, twice a day, will be started within 24 hours after randomization and maintained until 30 days after coronary artery bypass grafting.
Study NCT04850703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Radom Noise Stimulation
Description: tRNS against Dapoxetine in LPE patients
Study NCT04850703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Take Dapoxetine
Description: Dapoxetine against tRNS in LPE patients
Study NCT04850703 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Comparation EEG changes between Sham Group against tRNS and Dapoxetin participants
Description: Compare EEG parameters like Theta Rhythm and Coherence between three groups of participants: sham, tRNS participants and Dapoxetine participants groups.
Study NCT04850703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Compare LPE EEG endophenotype between participants and healthy controls
Description: Define as precisely as possible the electrophysiological endophenotype of Longlife Premature Ejaculation, using healthy humans who do not express the LPE EEG endophenotype
Study NCT05157451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life
Description: Ancillary studies
Study NCT05157451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05157451 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT05157451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Microsphere Radioembolization
Description: Given via injection
Study NCT06128590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation was applied before the procedures at an infrared wavelength of 808nm, at a power of 100mW, 1 point with a total energy of 8J, time of 80s, irradiance of 3.33W/cm² and radiant exposure of 266.66 J/cm2. The application point was on the retromolar region where the needle was inserted to perform the anesthetic, in a single application before the procedure.~The patient and operator were properly protected with goggles in both the control and experimental groups.
Study NCT06128590 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mepivacaine hydrochloride in combination with epinephrine
Description: The anesthetic of choice will be Mepivacaine, which is widely used in dentistry with duration between 1.5 and 2 minutes. The maximum recommended dose is 6.6 mg/Kg, not exceeding 400 mg or 11 anesthetic tubes.~It is a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) in combination with epinephrine 1:100,000 (0.01 mg/mL). Each vial contains 1.8 mL, 36 mg of mepivacaine hydrochloride, and 0.018 mg of epinephrine. All patients will use anesthetics from the same brand (DLA Pharmaceutical LTDA), one of the most widely used on the market. All patients will be anesthetized with tubes from the same batch, one tube per procedure.
Study NCT06128590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine hydrochloride in combination with epinephrine
Description: The anesthetic of choice will be Mepivacaine, which is widely used in dentistry with duration between 1.5 and 2 minutes. The maximum recommended dose is 6.6 mg/Kg, not exceeding 400 mg or 11 anesthetic tubes.~It is a sterile injectable solution of 2% mepivacaine hydrochloride (20 mg/mL) in combination with epinephrine 1:100,000 (0.01 mg/mL). Each vial contains 1.8 mL, 36 mg of mepivacaine hydrochloride, and 0.018 mg of epinephrine. All patients will use anesthetics from the same brand (DLA Pharmaceutical LTDA), one of the most widely used on the market. All patients will be anesthetized with tubes from the same batch, one tube per procedure.
Study NCT06128590 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation simulation
Description: The participants will be treated in the same manner as in group A. The person responsible for the application of FBM will simulate the irradiations by placing the device in the same location described for the experimental group, but the equipment will remain turned off. To prevent the participant from identifying their group, the activation sounds of the devices (beeps) will be recorded to simulate the device's operation.
Study NCT05494541 — intervention group
Intervention type: OTHER
Intervention: Crizanlizumab
Description: Patients who initiated crizanlizumab between November 1, 2019 and January 31, 2021 (index period) were selected into the treatment cohort.
Study NCT06554028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy TP regimen combined with Tislelizumab
Description: Induction chemotherapy TP regimen combined with Tislelizumab for 3 cycles: Cisplatin 37.5mg/m2 d1-2 q3w, Docetaxel 37.5mg/m2 d1and d3 q3w,Tislelizumab 200mg d3 q3w.~•Response rate of primary tumor or lymph nodes is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If the primary lesion reaches CR/PR and the lymph nodes reach CR, chemoradiotherapy based on cisplatin is conducted. If the primary lesion reaches CR/PR and lymph node PR/PD, cervical lymph node dissection will be performed, followed by radiotherapy/concurrent chemoradiotherapy. If the primary lesion is SD/PD, regardless of the condition of the lymph nodes, primary lesion resection and lymph node dissection should be performed, followed by adjuvant radiation/chemoradiation.~Other Names:~Docetaxel Cisplatin Paclitaxel
Study NCT06168396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatosensation Device
Description: The somatosensation device will be worn on the lower limb (either the residual limb for an amputee, or limb with decreased sensation for a participant with diabetic neuropathy) while performing outcome measures.
Study NCT06168396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline
Description: Participants will perform outcome measures without wearing the somatosensation device.
Study NCT05497375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The amount of intraoperative bleeding
Description: Total amount of intraoperative bleeding will be calculated in milliliters after the end of surgery.
Study NCT05497375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Quality of the intraoperative surgical field
Description: Quality of the intraoperative surgical field will be measured on a grade of 0-10 (0-1. no bleeding, 2-3. mild bleeding, 4-5. Mild to moderate bleeding, 6-7. moderate bleeding, 8-9. moderate to severe bleeding, 10. Severe bleeding)